AU Patent

AU2015352545B2 — Pyrrolobenzodiazepine-antibody conjugates

Assigned to ADC Therapeutics SA · Expires 2020-10-15 · 6y expired

What this patent protects

The present disclosure relates to the use of antibody-drug conjugates (ADCs) comprising pyrrolobenzodiazepine (PBD) dimers and anti-CD25 antibodies for use in treating disorders characterized by the presence of CD25+ve cells.

USPTO Abstract

The present disclosure relates to the use of antibody-drug conjugates (ADCs) comprising pyrrolobenzodiazepine (PBD) dimers and anti-CD25 antibodies for use in treating disorders characterized by the presence of CD25+ve cells.

Drugs covered by this patent

Patent Metadata

Patent number
AU2015352545B2
Jurisdiction
AU
Classification
—
Expires
2020-10-15
Drug substance claim
No
Drug product claim
No
Assignee
ADC Therapeutics SA
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.